계명대학교 의학도서관 Repository

Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study

Metadata Downloads
Author(s)
박철희
Alternative Author(s)
Park, Choal Hee
Publication Year
2016
Abstract
Objectives: The aim of this study was to evaluate the persistence with solifenacin
therapy over a 12-month period in patients with overactive bladder (OAB). Meth-
ods: This is a 52-week long, multicenter, prospective, observational study. The
subjects were individuals ≥ 18 years old with OAB symptoms for ≥ 3 months,
characterised by a total OAB Symptom Score (OABSS) of ≥ 3 and OABSS urgency
item score of ≥ 2. Patients were prescribed 5 mg or 10 mg of solifenacin once
daily for OAB symptoms. Drug persistence, reasons for discontinuation and factors
related to the persistence were evaluated. Results: A total of 1018 patients (329
men, 689 women) with a mean age of 59 years were included. The 52-week drug
persistence rate was 22.1%. The drug persistence rates at 12, 24 and 36 weeks
were 72.4%, 45.8% and 31.1% respectively. The three most common reasons for
discontinuing therapy included symptom improvement in 30.4%, lack of efficacy in
13.4%, and a switch to another antimuscarinic agent in 10.8%. Older patients
(odds ratio = 1.02, 95% CI: 1.01–1.04), and female patients (odds ratio = 1.94,
95% CI: 1.37–2.75) were more likely to continue the medication over the 12-
month period than were younger, male patients. The number of nocturia episodes
was negatively correlated with drug persistence (odds ratio = 0.83, 95% CI:
0.71–0.97). Conclusions: There was low persistence (22%) to solifenacin therapy
for OAB symptoms over a 12-month period. Older patients, female patients and
those with fewer episodes of nocturia were more persistent to therapy than were others.
Department
Dept. of Urology (비뇨의학)
Publisher
School of Medicine
Citation
Clinical Practice, Vol.70(4) : 351-357, 2016
Type
Article
ISSN
2044-9038
DOI
10.1111/ijcp.12783
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/33394
Authorize & License
  • AuthorizeOpen
  • EmbargoForever
Files in This Item:

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.